KR20140137867A - Composition comprising herbal mixture extract for treating or preventing inflammatory disease - Google Patents
Composition comprising herbal mixture extract for treating or preventing inflammatory disease Download PDFInfo
- Publication number
- KR20140137867A KR20140137867A KR1020130059035A KR20130059035A KR20140137867A KR 20140137867 A KR20140137867 A KR 20140137867A KR 1020130059035 A KR1020130059035 A KR 1020130059035A KR 20130059035 A KR20130059035 A KR 20130059035A KR 20140137867 A KR20140137867 A KR 20140137867A
- Authority
- KR
- South Korea
- Prior art keywords
- inflammatory
- mixed
- disease
- composition
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 9
- 241000580937 Acer tegmentosum Species 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 241000208689 Eucommia ulmoides Species 0.000 abstract 2
- 241000238876 Acari Species 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 230000036541 health Effects 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 240000000249 Morus alba Species 0.000 description 6
- 235000008708 Morus alba Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- -1 olive oil Chemical compound 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 244000019459 Cynara cardunculus Species 0.000 description 3
- 235000019106 Cynara scolymus Nutrition 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000016520 artichoke thistle Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 241000707822 Ulmus glabra Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241001143500 Aceraceae Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/20—Aceraceae (Maple family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 산겨릅나무 및 두충의 혼합 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물에 관한 것이다.
The present invention relates to a composition for the prophylaxis or treatment of inflammatory diseases, which comprises as an active ingredient, a mixed extract of a mountain elk and two mites.
면역이란 인체가 미생물에 의한 침입 과정에서 스스로를 지키기 위한 일종의 보호기작으로서 조직, 세포, 분자들이 감염원에 대하여 기관을 보호하는 것이다. 면역 감시 체계는 크게 선천적 면역계(innate immunosurveillance)와 획득 면역계(adaptive immunosurveillance)로 분류된다. 선천적 면역계는 대식세포 및 자연 살해 세포(natural killer cell) 등을 포함하는 백혈구, 사이토카인(cytokine) 등으로 구성되어 있어 감염에 대한 적응 면역이 발생하기 전에 신속하게 반응하여 1차 방어 역할을 한다. 선천적 면역계에서 생체 방어 기구의 최전선을 담당하는 대식세포는 숙주의 방어기구의 일부로서 면역계에 매우 중요한 역할을 수행하며 외부물질 침입을 가장 먼저 인지하여 체액성 면역과 세포성 면역에 관여하고 대식세포가 활성화되면 증식과 확산 능력의 향상 등과 같은 세포의 형태적 변화뿐만 아니라 대식능력의 증강, NO(nitric oxide) 및 사이토카인 생성의 향상을 수반하여 종국적으로 암세포와 각종 유해 균의 성장을 억제시킬 수 있는 것으로 여겨진다. 최근에는 이러한 면역 작용을 천연물질로 증진시키려는 연구에 대한 관심이 부각되고 있다.Immunity is a kind of protection mechanism for the human body to protect itself during the microbial invasion process, in which tissues, cells and molecules protect the organ against the infectious agent. Immune surveillance systems are classified into innate immunosurveillance and adaptive immunosurveillance. The innate immune system consists of leukocytes and cytokines, including macrophages and natural killer cells, and plays a primary defense role by reacting quickly before adaptive immunity to infection occurs. In the innate immune system, macrophages, which are responsible for the frontiers of biological defense mechanisms, play a very important role in the immune system as part of host defense mechanisms. They are the first to recognize foreign substance intrusion and are involved in humoral immunity and cellular immunity. When activated, not only the morphological changes of the cells such as the proliferation and spreading ability, but also the enhancement of the macrophage capacity, the improvement of the NO (nitric oxide) and the cytokine production, and finally the growth of cancer cells and various harmful bacteria ≪ / RTI > In recent years, there has been a growing interest in research aimed at promoting such immune actions as natural substances.
염증 반응은 병원체에 의한 감염이나 조직의 손상과 같은 다양한 요인에 의해 일어나는 생체 방어 반응으로, 감염 부위나 손상 부위에만 피해를 국한시키기 위한 초기 보호작용을 수행한다. 대부분의 경우, 이러한 염증 반응은 내재면역의 구성 요소를 이용한 병원성 요인의 제거 및 특이적 적응면역의 유도 등으로 이어진다.Inflammation reactions are bio-defense reactions caused by various factors such as infection by pathogens or tissue damage, and they perform an initial protective action to confine the damage only to the infected area or damaged area. In most cases, this inflammatory response leads to the elimination of pathogenic factors and the induction of specific adaptive immunity using components of endogenous immunity.
한편, 산겨릅나무(Acer tegmentosum M.)는 단풍나무과(Aceraceae)의 낙엽활엽 소교목으로서 국내 중부이북의 고산지대와 만주, 아무르와 우수리강 유역의 일부 산지에만 분포하고 있으며 참겨릅나무, 산저릅나무, 봉목이라고도 하며 민간에서는 벌나무, 산청목으로 알려져 있다. 산겨릅나무는 위암, 간암, 폐암 및 유방암 세포 등에서 암세포 생육억제 효과가 있음이 밝혀졌다. On the other hand, Acer tegmentosum M. is a deciduous broad-leaved arboreous tree of Aceraceae, which is distributed only in mountainous areas in the north of central part of Korea, in Manchuria, It is also known as a tree or a suture. It was found that the mountain elk had an inhibitory effect on cancer cell growth in gastric cancer, liver cancer, lung cancer and breast cancer cells.
두충(Eucommia ulmoides Oliver)은 중국의 호북, 사천성 등지가 원지산지로 알려져 있는 두충나무과(Eucommiaceae)에 속하는 낙엽교목으로서 생약학에서는 여러 해 묵은 두충나무의 나무껍질을 벗겨 말린 것을 말한다. 두충은 강장, 진정, 진통작용 등이 있는 것으로 알려져 있고, 혈압 강하작용이 있어 고혈압 등의 질병을 예방하는데 사용되었다. Eucommia ulmoides Oliver is a deciduous arboreous tree belonging to Eucommiaceae, which is known as the origin of Hubei and Sichuan provinces in China. It is known to have tonic, sedative and analgesic effects and has been used to prevent diseases such as hypertension due to blood pressure lowering action.
상기한 바와 같이, 산겨릅나무 및 두충의 다양한 약리 효과가 알려져 있지만, 이들의 혼합 추출물의 항염증 활성에 대한 연구는 미미한 실정이다. As described above, although various pharmacological effects of the acid elk and the two species are known, there is little research on the anti-inflammatory activity of the mixed extract thereof.
이에 본 발명자들은, 천연물질로부터 유래한 신규한 항염증 제제를 개발하기 위한 노력을 계속한 결과, 산겨릅나무 및 두충의 혼합 추출물이 LPS로 유도된 염증 반응을 감소시키는 우수한 효과가 있음을 확인함으로써, 본 발명을 완성하였다.
As a result of continuing efforts to develop new anti-inflammatory agents derived from natural materials, the inventors of the present invention have found that the mixed extracts of acid eletris and two mites have an excellent effect of reducing the inflammatory response induced by LPS , Thereby completing the present invention.
본 발명의 목적은 산겨릅나무 및 두충의 혼합 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for the prevention or treatment of inflammatory diseases, which comprises a mixed extract of a mountain elk and two mites as an active ingredient.
본 발명의 또 다른 목적은 산겨릅나무 및 두충의 혼합 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 개선용 식품 조성물을 제공하는 것이다.
It is still another object of the present invention to provide a food composition for preventing or ameliorating an inflammatory disease, which comprises a mixed extract of a mountain elk and two mites as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 산겨릅나무 및 두충의 혼합 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물을 제공한다. In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of an inflammatory disease, which comprises a mixed extract of a mountain elk and two insects as an active ingredient.
또한 본 발명은 산겨릅나무 및 두충의 혼합 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 개선용 식품 조성물을 제공한다.
The present invention also provides a food composition for preventing or ameliorating an inflammatory disease, which comprises a mixed extract of a mountain elk and two mites as an active ingredient.
본 발명에 따른 산겨릅나무 및 두충의 혼합 추출물은 LPS로 유도된 염증 반응을 감소시키는 등 단독 추출물에 비해 현저하게 우수한 항염증 효과를 가지고 있어, 염증성 질환의 예방 또는 치료에 유용하게 이용될 수 있다.
The mixed extract of a plant or a plant of the present invention has remarkably excellent antiinflammatory effect compared to a single extract, such as reducing the inflammatory response induced by LPS, and thus can be effectively used for the prevention or treatment of inflammatory diseases .
도 1 은 본 발명의 산겨릅나무(산청목) 및 두충의 혼합 추출물의 항산화 활성을 나타낸 도이다.
도 2는 본 발명의 산겨릅나무(산청목) 및 두충의 혼합 추출물의 항염증 활성을 나타낸 도이다. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a graph showing the antioxidative activity of a mixed extract of a mountain elk (chrysanthemum morifolium) and two mites of the present invention. Fig.
Fig. 2 is a graph showing the anti-inflammatory activity of a mixed extract of a mountain elk (aquamarina) of the present invention and a mite.
본 발명은 산겨릅나무 및 두충의 혼합 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물을 제공한다.The present invention provides a composition for the prevention or treatment of inflammatory diseases, which comprises a mixed extract of a mountain elk and two mites as an active ingredient.
상기 조성물은 약학적 조성물 또는 식품 조성물을 포함한다.
The composition comprises a pharmaceutical composition or a food composition.
이하, 본 발명에 대하여 보다 상세히 설명한다. Hereinafter, the present invention will be described in more detail.
본 발명의 조성물에서 유효성분인 산겨릅나무 및 두충의 혼합 추출물은 하기와 같은 방법으로 수득될 수 있다. Mixed extracts of the active ingredients, acid elk and two mites, in the composition of the present invention can be obtained by the following method.
먼저, 산겨릅나무 및 두충을 각각 물로 세척하여 이물질을 제거한 후, 그늘에서 건조하고 분쇄한다. 산겨릅나무 및 두충은 재배한 것 또는 시판되는 것 등을 제한없이 사용할 수 있다. 상기 산겨릅나무 또는 두충 분말에 약 2 내지 20배, 바람직하게는 3~10배 부피의 용매를 가하여 완전히 침지되도록 한다. 상기 추출 용매는 이에 제한되지 않으나, 물, 탄소수 1 내지 4의 알코올, 이들의 혼합용매로부터 선택된 1종 이상의 용매를 이용할 수 있으며, 바람직하게는 물이다. 추출 방법은 실온에서 함침하거나 가온할 수 있으며, 바람직하게는 50 내지 90℃, 보다 바람직하게는 85℃ 내지 90℃에서 추출한다. 상기 추출물을 여과 및 감압 농축하여 산겨릅나무 추출물 또는 두충 추출물을 수득한 후, 이를 혼합하여 산겨릅나무 및 두충의 혼합 추출물을 수득한다. First, the mountain elm and the two insects are washed with water to remove foreign matter, and then dried and crushed in the shade. Cultivated or harvested species can be used without limitation. A solvent having a volume of about 2 to 20 times, preferably 3 to 10 times the volume of the above-mentioned sunflower or quadricepsum powder is added to complete immersion. The extraction solvent is not limited thereto, but at least one solvent selected from water, alcohols having 1 to 4 carbon atoms, and a mixed solvent thereof may be used, and water is preferable. The extraction method can be impregnated or warmed at room temperature, and is preferably extracted at 50 to 90 占 폚, more preferably 85 to 90 占 폚. The extract is filtered and concentrated under reduced pressure to obtain an acid elek extract or mulberry extract, which are then mixed to obtain a mixed extract of a mountain elk and two mites.
상기 산겨릅나무 및 두충의 혼합 비율은 60내지 70 : 30 내지 40의 중량비이며 , 바람직하게는 65 : 35의 중량비이다. 상기 혼합 비율의 범위를 벗어날 경우에는 산겨릅나무 또는 두충 추출물을 단독으로 사용한 경우와 비교할 때 항염증 효과면에서 큰 차이가 없으며, 부작용의 우려가 있다. The mixing ratio of the above-mentioned mountain elk and the two species is in a weight ratio of 60 to 70: 30 to 40, preferably 65: 35. When the mixing ratio is out of the above range, there is no significant difference in the anti-inflammatory effect as compared with the case of using alone or in combination with the extract of mulberry or mulberry, and there is a risk of side effects.
본 발명에 따른 산겨릅나무 및 두충의 혼합 추출물은 LPS로 유도된 염증 반응을 감소시키는 등 단독 추출물에 비해 현저하게 우수한 항염증 효과를 가지고 있어, 염증성 질환의 예방 또는 치료에 유용하게 이용될 수 있다.The mixed extracts of the present invention of the present invention have remarkably excellent anti-inflammatory effect as compared with the single extracts such as reducing the inflammatory response induced by LPS, and thus can be usefully used for the prevention or treatment of inflammatory diseases .
상기 염증성 질환은 일반적인 염증 질환을 모두 포함하며, 바람직하게는 위염, 비염, 결막염, 천식, 피부염, 아토피성 피부염, 염증성 장질환, 염증성 간질환, 염증성 폐질환, 염증성 혈관질환, 염증성 류마티스성 관절염, 건선, 다발성 경화증 및 정맥두염 등을 포함하나, 이에 한정되는 것은 아니다.
The inflammatory disease includes all common inflammatory diseases and is preferably selected from the group consisting of gastritis, rhinitis, conjunctivitis, asthma, dermatitis, atopic dermatitis, inflammatory bowel disease, inflammatory liver disease, inflammatory lung disease, inflammatory vascular disease, inflammatory rheumatoid arthritis, Psoriasis, multiple sclerosis and venous sinusitis, and the like.
본 발명의 조성물은 산겨릅나무 및 두충의 혼합 추출물과 함께 항염증 효과를 갖는 공지의 유효성분을 1종 이상 더 함유할 수 있다. The composition of the present invention may contain at least one known active ingredient having antiinflammatory effect together with a mixed extract of a mountain elk and two mites.
본 발명의 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. 또한 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 당해 기술 분야에 알려진 적합한 제제는 문헌 (Remington's Pharmaceutical Science, 최근, Mack Publishing Company, Easton PA)에 개시되어 있는 것을 사용하는 것이 바람직하다. 상기 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등이 있다. 상기 조성물을 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로오스, 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 또한, 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose , Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the non-aqueous solvent and suspension include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명에서 사용되는 용어 "투여"는 임의의 적절한 방법으로 개체에게 소정의 본 발명의 조성물을 제공하는 것을 의미한다.The term "administering" as used herein is meant to provide any desired composition of the invention to a subject in any suitable manner.
본 발명의 약학적 조성물의 바람직한 투여량은 개체의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르며, 당업자에 의해 적절하게 선택될 수 있다. 바람직한 효과를 위해서, 본 발명의 혼합 추출물은 1일 1 mg/ kg 내지 10000 mg/kg의 양으로 투여할 수 있으며, 하루에 한번 또는 수 회 나누어 투여할 수도 있다. The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and body weight of the individual, the degree of disease, the drug form, the route of administration and the period of time, and can be appropriately selected by those skilled in the art. For the desired effect, the mixed extract of the present invention may be administered in an amount of 1 mg / kg to 10000 mg / kg per day, and may be administered once or several times a day.
본 발명의 약학적 조성물은 개체에게 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다. The pharmaceutical composition of the present invention may be administered to a subject in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
본 발명의 약학적 조성물은 염증성 질환의 예방 또는 치료를 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.
The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the prevention or treatment of inflammatory diseases.
본 발명에서, 건강기능식품이란 질병의 예방 또는 개선, 생체방어, 면역, 병후의 회복, 노화 억제 등 생체조절기능을 가지는 식품을 말하는 것으로, 장기적으로 복용하였을 때 인체에 무해하여야 한다. 본 발명의 산겨릅나무 및 두충의 혼합 추출물은 염증성 질환의 예방 또는 개선을 목적으로 건강기능식품에 첨가될 수 있다. 본 발명의 산겨릅나무 및 두충의 혼합 추출물을 식품 첨가물로 사용할 경우, 상기 산겨릅나무 및 두충의 혼합 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에 본 발명의 산겨릅나무 및 두충의 혼합 추출물은 원료에 대하여 15중량 % 이하, 바람직하게는 10 중량 % 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.In the present invention, the health functional food refers to a food having a biological control function such as prevention or improvement of disease, bio-defense, immunity, recovery after disease, suppression of aging, and should be harmless to human body when taken over a long period of time. The mixed extract of the present invention of the present invention can be added to a health functional food for the purpose of preventing or improving an inflammatory disease. When the mixed extract of the present invention is used as a food additive, the mixed extract of the above-mentioned acid elk and the two mites can be directly added or used together with other food or food ingredients, and can be appropriately used according to a conventional method . The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, in the production of foods or beverages, the mixed extracts of the present invention and the double crops of the present invention are added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 포함할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토오스, 수크로오스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml 당 일반적으로 약 0.01 내지 10 g, 바람직하게는 약 0.01 내지 0.1 g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharine and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 포함할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100중량부 당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
이하 본 발명의 이해를 돕기 위하여 바람직한 실시예, 실험예 및 제조예를 제시한다. 그러나 하기의 실시예, 실험예 및 제조예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예, 실험예 및 제조예에 의해 본 발명의 내용이 한정되는 것은 아니다.
Hereinafter, preferred embodiments, experimental examples, and production examples are provided to facilitate understanding of the present invention. However, the following examples, experimental examples and production examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples, experimental examples and production examples.
실시예 1. 산겨릅나무 및 두충의 혼합 추출물의 제조EXAMPLES Example 1. Preparation of Mixed Extracts of San.arcoma
1-1. 산겨릅나무 추출물의 제조1-1. Production of acid elite extract
산겨릅나무를 물로 세척하여 이물질을 제거한 후, 그늘에서 건조하고 분쇄하였다. 상기 산겨릅나무 분말 1kg을 85℃ 내지 90℃에서 24시간동안 증류수로 추출하고, 거름종이로 여과한 후, 농축하고 동결 건조하여 분말 형태의 산겨릅나무 추출물을 얻었다.
The mountain elm was washed with water to remove foreign matter, dried in the shade, and pulverized. 1 kg of the above-harvested artichoke powder was extracted with distilled water at 85 ° C to 90 ° C for 24 hours, filtered through filter paper, concentrated, and lyophilized to obtain powdered artichokes.
1-2. 두충 추출물의 제조1-2. Preparation of mulberry extract
두충을 물로 세척하여 이물질을 제거한 후, 그늘에서 건조하고 분쇄하였다. 상기 두충 분말 1kg을 85℃ 내지 90℃에서 24시간동안 증류수로 추출하고 거름종이로 여과한 후, 농축하고 동결 건조하여 분말 형태의 두충 추출물을 얻었다.
After removing the foreign substances by washing with water, they were dried and crushed in the shade. 1 kg of the bamboo powder was extracted with distilled water at 85 ° C to 90 ° C for 24 hours, filtered through filter paper, concentrated and lyophilized to obtain a powdery mugwort extract.
1-3. 산겨릅나무 추출물 및 두충 추출물의 혼합1-3. Mixture of acid elite extract and mulberry extract
상기 실시예 1-1 및 1-2에서 제조한 산겨릅나무 추출물 및 두충 추출물을6.5 : 3.5 의 중량비(w/w)로 균질하게 혼합하여 분말 상태의 혼합물을 제조하였다.The plant extracts and mulberry extracts prepared in Examples 1-1 and 1-2 were homogeneously mixed at a weight ratio (w / w) of 6.5: 3.5 to prepare a powdery mixture.
실험예 1. 항산화 활성 평가Experimental Example 1. Evaluation of Antioxidative Activity
상기 실시예 1에서 제조한 산겨릅나무 및 두충의 혼합 추출물의 항산화 활성을 평가하기 위해, 종래 공지된 Sakata 등의 방법(Biosci.Biotech. Biochem. 58: 1780-1783, 1994)을 응용하여 DPPH 자유 라디칼 소거능을 평가하였다. 대조군으로는 강력한 항산화제로 알려진 아스코르브산(Ascorbic acid)을 이용하였다. 그 결과를 도 1에 나타내었다. In order to evaluate the antioxidative activity of the mixed extracts of the acid eletris and two mites prepared in Example 1, a method of Sakata et al. (Biosci.Biotech. Biochem. 58: 1780-1783, 1994) The radical scavenging ability was evaluated. Ascorbic acid, a powerful antioxidant, was used as a control. The results are shown in Fig.
도 1에 나타낸 바와 같이, 본 발명에 따른 산겨릅나무 및 두충의 혼합 추출물의 IC50는 10 ug/ml미만으로 확인되었으며, 산겨릅나무 단독 추출물 및 두충 단독 추출물에 비해 우수한 항산화 활성을 가지고 있음을 확인하였다.
As shown in FIG. 1, the IC 50 of the mixed extracts of the present invention was found to be less than 10 ug / ml, and it was found to have an excellent antioxidative activity compared to the extract alone and the extracts Respectively.
실험예 2. 항염증 활성 평가Experimental Example 2. Evaluation of anti-inflammatory activity
상기 실시예 1에서 제조한 산겨릅나무 및 두충의 혼합 추출물의 항염증 활성을 평가하기 위해 하기와 같은 실험을 수행하였다. 실험에는 대식세포주인 RAW264.7 세포를 이용하였으며, 상기 세포는 한국세포주은행(KTCC, Seoul, Korea)에서 분양받아 사용하였다. RAW264.7 세포는 FBS를 함유한 DMEM 배지(Gibco, Grand Island, NY, USA)에 넣은 후, 37°C, 5% CO2로 조절된 배양기에서 유지하였다. 먼저, Raw264.7 세포를 96-웰 플레이트에 2ⅹ105 cell/well의 농도로 분주한 후, 36시간동안 배양하였다. 그 후 혈청(Serum)을 제외한 DMEM 배지로 배지를 바꿔준 후, 24시간 동안 더 배양하였다. 각 웰에 상기 실시예 1에서 제조한 산겨릅나무 및 두충의 혼합 추출물을 최종 농도 100 ug/ml이 되게 처리하였다. 2시간 후 각 웰에 LPS(lipopolysaccharide)를 최종 농도 1 ug/ml로 처리하여 24시간 동안 배양하였다. 이 후 MTT 용액 (5 mg/ml)을 가하고 37°C 에서 4시간 동안 배양한 후, MTT를 환원시켜 생성된 포르마잔(formazan)이 배지에 떨어져나가지 않도록 배지를 조심스럽게 제거하였다. 마지막으로 각 웰에 DMSO 100 ul 씩 분주한 후 540 nm에서 흡광도를 측정하였다. 그 결과를 도 2에 나타내었다. The following experiment was carried out to evaluate the anti-inflammatory activity of the mixed extracts of the acid eletris and two mites prepared in Example 1 above. In the experiment, RAW264.7 cells were used as macrophages, and the cells were used in Korean Cell Line Bank (KTCC, Seoul, Korea). RAW264.7 cells were placed in DMEM medium (Gibco, Grand Island, NY, USA) containing FBS and maintained in an incubator maintained at 37 ° C, 5% CO 2 . First, Raw264.7 cells were seeded in 96-well plates at a concentration of 2 x 10 cells / well and cultured for 36 hours. After that, the medium was changed with DMEM medium except for serum, and the cells were further cultured for 24 hours. Each of the wells was treated with the mixed extracts of the acid eletris and two mites prepared in Example 1 to a final concentration of 100 ug / ml. After 2 hours, each well was treated with LPS (lipopolysaccharide) at a final concentration of 1 ug / ml and cultured for 24 hours. After that, MTT solution (5 mg / ml) was added and cultured at 37 ° C for 4 hours. Then, MTT was reduced and the medium was carefully removed so that the formazan produced did not fall on the medium. Finally, 100 μl of DMSO was added to each well, and the absorbance was measured at 540 nm. The results are shown in Fig.
도 2에 나타낸 바와 같이, LPS만을 처리한 대조군에서는 무처리구(Control)에 비해 약 20%의 세포 사멸이 유발된 반면, 본 발명에 따른 산겨릅나무 및 두충의 혼합 추출물을 처리한 군에서는 세포 생존율이 무처리구 수준으로 증가함을 확인하였으며, 특히 산겨릅나무 단독 추출물 또는 두충 단독 추출물에 비해 우수한 효과를 나타냄을 확인하였다. 상기 결과를 통하여, 본 발명의 산겨릅나무 및 두충의 혼합 추출물은 LPS로 유도된 염증 반응을 억제하는 우수한 효과를 가짐을 확인하였다.
As shown in FIG. 2, in the control group treated with LPS only, about 20% of cell death was induced compared with control, whereas in the group treated with the mixed extract of the present invention, cell survival rate And it was confirmed that the extracts showed better effect than the single extract or the extracts of the extracts of the artichoke alone. From the above results, it was confirmed that the mixed extract of the present invention of the present invention has an excellent effect of inhibiting the inflammatory reaction induced by LPS.
이하 본 발명의 약학적 조성물 및 식품 조성물의 제제예를 설명하나, 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.
Hereinafter, the pharmaceutical composition of the present invention and the preparation example of the food composition will be described, but the present invention is not intended to be limited but is specifically described .
제제예 1. 약학적 조성물의 제조 Formulation Example 1. Preparation of a pharmaceutical composition
1-1. 산제의 제조1-1. Manufacture of Powder
산겨릅나무 및 두충의 혼합 추출물 20 mg Mixed extract of mountain elk and two
유당 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.
The above components are mixed and filled in airtight bags to prepare powders.
1-2. 정제의 제조1-2. Manufacture of tablets
산겨릅나무 및 두충의 혼합 추출물 10 mgMixed extract of mountain elk and two
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mgMagnesium stearate 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
1-3. 캡슐제의 제조1-3. Preparation of capsules
산겨릅나무 및 두충의 혼합 추출물 10 mgMixed extract of mountain elk and two
결정성 셀룰로오스 3 mgCrystalline cellulose 3 mg
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.
The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
1-4. 주사제의 제조1-4. Injection preparation
산겨릅나무 및 두충의 혼합 추출물 10 mgMixed extract of mountain elk and two
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile sterilized water for injection 2974 mg
Na2HPO4·2H2O 26 mgNa 2 HPO 4 .2H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2 ml) 상기의 성분 함량으로 제조한다.
(2 ml) per 1 ampoule in accordance with the usual injection preparation method.
1-5. 액제의 제조1-5. Manufacture of liquid agent
산겨릅나무 및 두충의 혼합 추출물 20 mgMixed extract of mountain elk and two
이성화당 10 g10 g per isomer
만니톨 5 g5 g mannitol
정제수 . 적량Purified water . Suitable amount
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ml로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.
Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.
제제예 2. 식품 조성물의 제조Formulation Example 2. Preparation of Food Composition
2-1. 건강식품의 제조2-1. Manufacture of health food
산겨릅나무 및 두충의 혼합 추출물 100 mg100 mg of mixed extract of mountain elk and two mites
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 μg Vitamin A
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mg0.15 mg of vitamin B2
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 μg Vitamin B12 0.2 μg
비타민 C 10 mg
비오틴 10 μg Biotin 10 μg
니코틴산아미드 1.7 mgNicotinic acid amide 1.7 mg
엽산 50 μg Folic acid 50 μg
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 mg1.75 mg of ferrous sulfate
산화아연 0.82 mg0.82 mg of zinc oxide
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgSecondary calcium phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.
Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
2-2. 건강음료의 제조2-2. Manufacture of health drinks
산겨릅나무 및 두충의 혼합 추출물 100 mg100 mg of mixed extract of mountain elk and two mites
비타민 C 15 gVitamin C 15 g
비타민 E(분말) 100 gVitamin E (powder) 100 g
젖산철 19.75 g19.75 g of ferrous lactate
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinic acid amide 3.5 g
비타민 A 0.2 gVitamin A 0.2 g
비타민 B1 0.25 gVitamin B1 0.25 g
비타민 B2 0.3 gVitamin B2 0.3 g
물 정량Water quantification
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 l 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 liter container, It is used in the production of the health beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.
Claims (6)
The present invention relates to a pharmaceutical composition for preventing or treating an inflammatory disease,
[Claim 2] The method according to claim 1, wherein the mixed extract is obtained by extracting a mixture of an acid eletris and a bug with at least one solvent selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms and a mixed solvent thereof. A pharmaceutical composition for preventing or treating.
The pharmaceutical composition for preventing or treating an inflammatory disease according to claim 1, wherein the mixed extract of a plant or a plant is mixed at a weight ratio of 60: 70 to 30: 40.
The method of claim 1, wherein the inflammatory disease is selected from the group consisting of gastritis, rhinitis, conjunctivitis, asthma, dermatitis, atopic dermatitis, inflammatory bowel disease, inflammatory liver disease, inflammatory lung disease, inflammatory vascular disease, inflammatory rheumatoid arthritis, psoriasis, Wherein the pharmaceutical composition is at least one selected from the group consisting of oral hypogonadism, psoriasis, and sinusitis.
A food composition for preventing or improving an inflammatory disease, comprising as an active ingredient a mixed extract of a plant or a plant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130059035A KR102123832B1 (en) | 2013-05-24 | 2013-05-24 | Composition comprising herbal mixture extract for treating or preventing inflammatory disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130059035A KR102123832B1 (en) | 2013-05-24 | 2013-05-24 | Composition comprising herbal mixture extract for treating or preventing inflammatory disease |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140137867A true KR20140137867A (en) | 2014-12-03 |
KR102123832B1 KR102123832B1 (en) | 2020-06-17 |
Family
ID=52457542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130059035A KR102123832B1 (en) | 2013-05-24 | 2013-05-24 | Composition comprising herbal mixture extract for treating or preventing inflammatory disease |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102123832B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210155899A (en) * | 2020-06-17 | 2021-12-24 | 대한민국(농촌진흥청장) | Composition comprising NueDongChungHaCho(Paecilomyces tenuipes) water extract for preventing or treating inflammatory disease |
KR20210155901A (en) * | 2020-06-17 | 2021-12-24 | 대한민국(농촌진흥청장) | Composition for enhancing immunity comprising NueDongChungHaCho(Paecilomyces tenuipes) water extract |
KR20210155900A (en) * | 2020-06-17 | 2021-12-24 | 대한민국(농촌진흥청장) | Composition comprising NueDongChungHaCho(Paecilomyces tenuipes) alcohol extract for preventing or treating inflammatory disease |
WO2023136407A1 (en) * | 2022-01-17 | 2023-07-20 | 경상국립대학교산학협력단 | Composition comprising eucommia ulmoides leaf fraction for treating or preventing pulmonary diseases caused by fine dust |
WO2023136405A1 (en) * | 2022-01-17 | 2023-07-20 | 경상국립대학교산학협력단 | Composition comprising eucommia ulmoides leaf fraction for preventing or treating brain diseases caused by particulate matter |
WO2023136406A1 (en) * | 2022-01-17 | 2023-07-20 | 경상국립대학교산학협력단 | Composition for preventing or treating bowel diseases caused by fine dust comprising eucommia ulmoides leaf fraction |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030095912A (en) | 2002-06-15 | 2003-12-24 | (주)하이엔텍 | The catalyst for removing injuriousness gas and manufacturing method of the same |
KR20040004346A (en) * | 2003-12-23 | 2004-01-13 | 장태순 | Food composition for prophylaxis or improvement of inflammatory diseases and process for preparation thereof |
KR20070028829A (en) * | 2005-09-08 | 2007-03-13 | 주식회사 다원 | Composition comprising the extract of dioscorea quinqueloba and acer tegmentosum showing anti-oxidative, anti-aging, anti-lipidperoxidative, anti-edema and expectorant activity |
KR20080091743A (en) * | 2008-09-22 | 2008-10-14 | 광주과학기술원 | Pharmaceutical and food compositions for preventing or treating arthritis comprising lactic acid bacteria and collagen as active ingredients |
-
2013
- 2013-05-24 KR KR1020130059035A patent/KR102123832B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030095912A (en) | 2002-06-15 | 2003-12-24 | (주)하이엔텍 | The catalyst for removing injuriousness gas and manufacturing method of the same |
KR20040004346A (en) * | 2003-12-23 | 2004-01-13 | 장태순 | Food composition for prophylaxis or improvement of inflammatory diseases and process for preparation thereof |
KR20070028829A (en) * | 2005-09-08 | 2007-03-13 | 주식회사 다원 | Composition comprising the extract of dioscorea quinqueloba and acer tegmentosum showing anti-oxidative, anti-aging, anti-lipidperoxidative, anti-edema and expectorant activity |
KR20080091743A (en) * | 2008-09-22 | 2008-10-14 | 광주과학기술원 | Pharmaceutical and food compositions for preventing or treating arthritis comprising lactic acid bacteria and collagen as active ingredients |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210155899A (en) * | 2020-06-17 | 2021-12-24 | 대한민국(농촌진흥청장) | Composition comprising NueDongChungHaCho(Paecilomyces tenuipes) water extract for preventing or treating inflammatory disease |
KR20210155901A (en) * | 2020-06-17 | 2021-12-24 | 대한민국(농촌진흥청장) | Composition for enhancing immunity comprising NueDongChungHaCho(Paecilomyces tenuipes) water extract |
KR20210155900A (en) * | 2020-06-17 | 2021-12-24 | 대한민국(농촌진흥청장) | Composition comprising NueDongChungHaCho(Paecilomyces tenuipes) alcohol extract for preventing or treating inflammatory disease |
WO2023136407A1 (en) * | 2022-01-17 | 2023-07-20 | 경상국립대학교산학협력단 | Composition comprising eucommia ulmoides leaf fraction for treating or preventing pulmonary diseases caused by fine dust |
WO2023136405A1 (en) * | 2022-01-17 | 2023-07-20 | 경상국립대학교산학협력단 | Composition comprising eucommia ulmoides leaf fraction for preventing or treating brain diseases caused by particulate matter |
WO2023136406A1 (en) * | 2022-01-17 | 2023-07-20 | 경상국립대학교산학협력단 | Composition for preventing or treating bowel diseases caused by fine dust comprising eucommia ulmoides leaf fraction |
Also Published As
Publication number | Publication date |
---|---|
KR102123832B1 (en) | 2020-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101668845B1 (en) | A pharmaceutical composition for preventing or treating bone diseases comprising Dendropanax morbifera extract | |
KR20140137867A (en) | Composition comprising herbal mixture extract for treating or preventing inflammatory disease | |
KR101691205B1 (en) | Composition comprising herbal extract for preventing or treating fatty liver disease | |
KR100793081B1 (en) | A composition comprising the compound isolated from the extract of gracilaria verucosa for preventing and treating inflammatory disease | |
KR20140067826A (en) | Composition comprising sargassum fulvellum extract for preventing or treating inflammatory diseases | |
KR101585074B1 (en) | Composition comprising roasted Cucumis melo L. var makuwa Makino seed extract for treating or preventing cancer | |
JP4537024B2 (en) | Inflammatory disease preventive / therapeutic agent | |
KR101899555B1 (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
KR101483585B1 (en) | Composition comprising complex extract of Astragalus Membranaceus, Schisandra Chinesis and Platycodon grandiflorum for preventing or treating inflammatory disease | |
KR20180118413A (en) | Composition comprising Cordycepin as an effective ingredient for preventing or treating of Liver cancer and Method for preparing Butanol fraction of Cordyceps militaris | |
KR20140095132A (en) | fermented corni fructus composition with antioxidant activity and method of making the same | |
KR102092729B1 (en) | Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract | |
KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
KR20210140933A (en) | Composition for preventing or treating sarcopenia comprising blueberry extract | |
KR20150080131A (en) | Composition containing Reseda luteola L. extract for treating or preventing inflammatory diseases | |
KR101540957B1 (en) | Composition containing moojabanchromanol b for preventing or treating inflammatory disease | |
KR101470613B1 (en) | Composition comprising latifolin for preventing or treating inflammatory diseases | |
KR101406126B1 (en) | Composition containing Hedyotis diffusa extract for treating or preventing obesity | |
KR101578404B1 (en) | Composition for prevention or treatment of cancer containing extract or fraction of Euphorbia L. | |
KR20180118412A (en) | Composition comprising Cordycepin as an effective ingredient for preventing or treating of Liver cancer and Method for preparing Ethyl acetate fraction of Cordyceps militaris | |
KR102430399B1 (en) | A composition for improving, preventing and treating of gastrointestinal disease | |
KR102183915B1 (en) | Composition containing complex extracts for improving blood circulation | |
KR20170076587A (en) | Composition comprising Monoterpenyl magnolol as an effective ingredient for preventing or treating of obesity, hyperlipidemia or fatty Liver and Method for preparing fraction of Magnolia cortex | |
KR20150087715A (en) | Composition containing Artemisia annua extract, and artemisinin or dihydroartemisinin from Artemisia annua extract for preventing or treating liver cancer | |
KR20150090646A (en) | Composition containing garlic sprouting extract for preventing or treating brain disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |